4,4'-dimethyl-1'-(3-piperidin-4-yl-propyl)-1H,1'H-[2,5']bibenzoimidazolyl | 1161426-00-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4,4'-dimethyl-1'-(3-piperidin-4-yl-propyl)-1H,1'H-[2,5']bibenzoimidazolyl
• 英文别名: 4-methyl-5-(4-methyl-1H-benzimidazol-2-yl)-1-(3-piperidin-4-ylpropyl)benzimidazole
• CAS: 1161426-00-1
• 化学式: C₂₄H₂₉N₅
• 分子量: 387.528
• InChiKey: NFILCQMYQMBTMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  58.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
  申请人：Kindrachuk David E.

  公开号：US20090156613A1

  公开（公告）日：2009-06-18

  Bicyclic heteroaryl-substituted imidazole compounds are described, which are useful as H 4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H 4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H 4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

  描述了具有双环杂环芳基取代的咪唑化合物，这些化合物可用作H4受体调节剂。这种化合物可以用于制备药物组合物，用于调节组脊髓H4受体活性以及治疗由H4受体活性介导的疾病状态、紊乱和症状，例如过敏、哮喘、自身免疫疾病和瘙痒症。
• Heteroaryl Rheb inhibitors and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US11339144B2

  公开（公告）日：2022-05-24

  The present invention provides compounds of general Formula I and I′: compositions thereof, and methods of using same to treat Rheb-mediated disorders.

  本发明提供通式I和I′的化合物： 其组合物，以及用其治疗 Rheb 介导的疾病的方法。
• H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS
  申请人：SENSORION

  公开号：US20150176010A1

  公开（公告）日：2015-06-25

  The invention relates to Histamine type 4 receptor (H4R) inhibitors for treating tinnitus.
• HETEROARYL RHEB INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20210238165A1

  公开（公告）日：2021-08-05

  The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.
• US8084466B2
  申请人：——

  公开号：US8084466B2

  公开（公告）日：2011-12-27